What CPT codes are used for amniotic membrane allograft application in 2026?

CPT codes 15271–15278 are used for skin substitute graft application based on anatomic site and wound surface area. CPT 15271 covers trunk, arms, and legs for the first 25 cm²; CPT 15272 is the add-on for each additional 25 cm². CPT 15275 covers face, neck, hands, feet, and genitalia for the first 25 cm²; CPT 15276 is the corresponding add-on.

What HCPCS code applies to AmnioAMP-MP in 2026?

AmnioAMP-MP is coded under HCPCS Q4250, per square centimeter. This code was established by CMS effective October 1, 2020 and remains active for 2026 billing. Rampart DL Matrix uses HCPCS Q4347.

What is the 2026 Medicare reimbursement rate for amniotic membrane allografts?

Under the CY 2026 Medicare Physician Fee Schedule Final Rule, skin substitute products are reimbursed at a single national flat rate of approximately $127 per cm². Application procedures bill separately under CPT 15271–15278. The flat rate replaces prior product-specific ASP+6% pricing and applies across physician offices, hospital outpatient departments, and ambulatory surgical centers.

How do I bill both the product and the application procedure for an amniotic membrane allograft?

Report the product on one claim line with the appropriate HCPCS Level II code (e.g., Q4250 for AmnioAMP-MP) and the number of cm² applied. Report the application procedure on a separate claim line with the correct CPT code (15271–15278) based on anatomic site and total wound surface area. Both must be supported by documentation from the same clinical record, including wound measurements, indication, and medical necessity.

Did the 2026 CMS flat rate eliminate the need for prior authorization?

No. The 2026 flat rate changed payment methodology but did not change coverage requirements. Medicare Advantage and commercial plans may still require prior authorization. CMS also withdrew the scheduled multi-MAC local coverage determinations for skin substitute grafts in DFUs and VLUs on December 24, 2025, so coverage analysis remains MAC-jurisdiction and payer specific.

What documentation is required for amniotic membrane allograft claims?

Required documentation includes: wound etiology and duration, prior conservative therapy and its failure, vascular assessment, debridement details, pre- and post-debridement wound measurements, product name and HCPCS code, product size opened and area applied, fixation method, secondary dressing, offloading or compression instructions, and planned follow-up. Photographs support documentation when HIPAA-compliant.

What clinical evidence supports amniotic membrane allograft use?

Systematic reviews and meta-analyses support amniotic membrane allografts for diabetic foot ulcers, showing improved healing rates compared with standard care alone. Recent evidence includes Lakmal K et al. (2021) systematic review on rational use in DFU treatment, and Toman J et al. (2025) cost-effectiveness analysis following Mohs surgery. These studies inform payer coverage decisions and clinical adoption.

Amniotic Membrane Allograft Coding: 2026 HCPCS & CPT Guide

Direct Answer: Amniotic membrane allografts for wound coverage are coded with HCPCS Level II product codes (Q4250 for AmnioAMP-MP, Q4347 for Rampart DL Matrix) and CPT application codes 15271–15278 based on anatomic site and wound surface area. Under the CY 2026 Medicare Physician Fee Schedule Final Rule, non-BLA skin substitute products are reimbursed at a flat national rate of approximately $127 per cm². Product and procedure codes must be reported on separate claim lines with matching documentation from the same clinical record.

Key Takeaways: 2026 Amniotic Membrane Allograft Coding

Product codes: AmnioAMP-MP = HCPCS Q4250; Rampart DL Matrix = HCPCS Q4347. Verify current HCPCS assignment before billing — do not assume one placental product's code applies to another.
Application codes: CPT 15271–15278 based on anatomic site and total treated wound surface area. Pair the correct first-code and add-on-code for the measured area.
Flat-rate reimbursement: ~$127/cm² national rate under CMS 2026 final rule. Acquisition cost relative to this rate determines margin.
Coverage not automatic: The withdrawn multi-MAC LCDs did not eliminate coverage requirements. Verify current MAC and payer guidance for each indication and product.
Documentation is critical: Product and application codes must match wound measurements, diagnosis, and medical necessity in the clinical record.
Clinical evidence base: Systematic reviews support improved healing outcomes in diabetic foot ulcers and cost-effectiveness in surgical wound reconstruction.^1,3

Quick-Reference: 2026 HCPCS & CPT Codes for Amniotic Membrane Allografts

Code	Type	Description	2026 Context
Q4250	HCPCS Level II	AmnioAMP-MP, per cm²	Established by CMS effective October 1, 2020. Active for 2026. Bill per square centimeter applied.
Q4347	HCPCS Level II	Rampart DL Matrix, per cm²	Dual-layer dehydrated amniotic membrane allograft. Verify current code assignment with manufacturer reimbursement guidance.
15271	CPT	Skin substitute graft, trunk/arms/legs, first 25 cm²	Initial application on lower-extremity wounds (leg, thigh). Separate PFS payment for procedure.
15272	CPT	Add-on, each additional 25 cm² (trunk/arms/legs)	Use when total treated area exceeds 25 cm². Reports additional surface area beyond the first 25 cm².
15275	CPT	Skin substitute graft, face/neck/hands/feet/genitalia, first 25 cm²	Use for foot wounds when the anatomic site modifier applies. Verify site-specific payer edits.
15276	CPT	Add-on, each additional 25 cm² (face/neck/hands/feet/genitalia)	Add-on for foot wound areas exceeding 25 cm².
15273	CPT	Skin substitute graft, trunk/arms/legs, first 25 cm² (patient < 1 year)	Pediatric-specific code. Not applicable for typical adult wound care population.
15274	CPT	Add-on, each additional 25 cm² (pediatric)	Pediatric add-on code.

2026 CMS Payment Restructuring: What Changed

The CY 2026 Medicare Physician Fee Schedule Final Rule restructured skin substitute payment in two fundamental ways:

      Single national flat rate of approximately $127 per cm² replaces the prior ASP+6% product-specific pricing model. This rate applies uniformly to all non-BLA skin substitute products regardless of manufacturer, processing method, or regulatory pathway.
Skin substitute products reclassified as incident-to supplies in the physician office setting. Products are separately payable when used as part of a covered application procedure under the Physician Fee Schedule.
Low-cost HCPCS codes (C5271–C5278) deleted. All products now bill under standard HCPCS Level II codes.
Application procedures bill under CPT 15271–15278 across all settings — physician offices, hospital outpatient departments (OPPS), and ambulatory surgical centers (ASCs).

    

At the same time, CMS announced on December 24, 2025 that the final multi-MAC local coverage determinations for skin substitute grafts in diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), which had been scheduled for January 1, 2026, were withdrawn. The practical result: Medicare payment methodology changed nationally, but coverage analysis still depends on the patient, wound, payer, MAC jurisdiction, and documentation quality.

Margin implication: Products with acquisition cost significantly below $127/cm² produce positive margin per application. Procurement teams should calculate actual per-unit acquisition cost against the flat rate — a 24-month ambient-storage amniotic membrane allograft and a 15-day-expiry living construct are reimbursed at the same per-cm² rate.

For broader context on the 2026 CMS changes, see our CMS skin substitute reimbursement guide and Medicare coverage eligibility guide.

How CPT and HCPCS Work Together on a Single Claim

When an amniotic membrane allograft is applied, the claim requires two distinct components:

Claim Component	Coding System	What It Communicates	Example
Product	HCPCS Level II	Which biologic product was used and how many units (cm²)	Q4250 × 16 units (16 cm² of AmnioAMP-MP)
Application procedure	CPT Category I	Clinician work of wound evaluation, bed preparation, graft placement	15271 (trunk/leg, first 25 cm²)
Diagnosis	ICD-10-CM	Ulcer etiology, site, laterality, severity, and comorbid disease	E11.621 (Type 2 DM with foot ulcer), L97.519 (non-pressure chronic ulcer, right foot)

The most common denial trigger is a mismatch between the product code and the application code, or between either code and the diagnosis. Multi-code validation strategies — combining CPT, HCPCS, and ICD-10-CM codes rather than relying on a single code type — consistently improve claims accuracy and reduce audit risk in specialty billing.

Clinical Documentation Requirements

Strong documentation begins before the first graft application and continues through each encounter:

      Pre-application: Ulcer duration, diabetes control factors (for DFU), neuropathy status, offloading plan, vascular assessment, infection evaluation, and failure of conservative therapy.
At application: Pre- and post-debridement wound measurements, wound surface area calculation, product name and HCPCS code, product size opened, cm² applied, any discarded amount if required by payer policy, fixation method, secondary dressing, offloading or compression instructions, and planned reassessment interval.
Follow-up: Serial wound measurements, percentage area reduction, presence or absence of infection, response to treatment, and documentation of medical necessity for continued application.

    

Audit defensibility principle: The clinical note, charge ticket, inventory log, and product lot record must tell the same story. If the wound is not improving after several applications, reassess perfusion, infection, pressure, edema, nutrition, adherence, and diagnosis before continuing. Reimbursement defensibility weakens when repeated applications continue without measurable clinical response or a documented reason to continue.

CMS established HCPCS Q4250 for AmnioAMP-MP effective October 1, 2020 through the biannual HCPCS drug and biological application process.

Payer-Specific Considerations for 2026

Setting	2026 Payment Mechanism	Operational Focus
Physician office / non-facility	Skin substitute products paid as incident-to supplies when used with a covered application procedure under PFS policy.	Pair product HCPCS units with the correct CPT application code, wound size, site, diagnosis, and medical-necessity documentation.
Hospital outpatient department	Products unpackaged from application services and assigned to skin substitute APC groupings.	Confirm OPPS status indicator, APC assignment, revenue code workflow, charge master configuration, and payer-specific edits.
Medicare Advantage / commercial	Coverage and payment may differ from Original Medicare and may require prior authorization.	Check plan policy, covered indications, frequency limits, product lists, documentation requirements, and denial appeal language.

Clinical Evidence Supporting Amniotic Allograft Use

Reimbursement policies increasingly require evidence-informed product selection. A systematic review and meta-analysis of seven randomized controlled trials involving 465 participants found that human amniotic membrane plus standard care improved complete DFU healing compared with standard care alone at 6 and 12 weeks, with shorter time to closure and no significant increase in adverse events.⁴ Earlier prospective randomized work by Zelen and colleagues found improved healing outcomes with amniotic membrane wound grafts in DFU management.⁵

For VLUs, randomized evidence supports amniotic membrane allografts as an adjunct to multilayer compression in selected nonhealing ulcers. Serena and colleagues reported multicenter data evaluating dehydrated human amnion/chorion membrane plus compression compared with compression alone, with follow-up analyses linking early area reduction to later healing.⁶

Recent studies also demonstrate the value of amniotic membrane allografts in diabetic foot ulcer treatment. Lakmal K and colleagues conducted a systematic review on the rational use of amniotic membrane allografts in DFU treatment, supporting their clinical utility in evidence-based wound management protocols.¹

Most recently, Toman J and colleagues conducted a propensity score-matched comparative cost-effectiveness analysis of placental allograft reconstruction of cutaneous wounds following Mohs surgery, demonstrating the economic benefits of these biological interventions in dermatologic surgical applications.³

These studies are not product-identical to every commercially available allograft, but they form part of the evidence base that payers and clinicians use when evaluating placental-derived wound biologics for coverage decisions.

Need amniotic membrane allografts with clear coding support for your wound center?

Request samples of amnioamp or Rampart at nextgenbiologicsusa.com/request-samples

References

Lakmal K, Samaranayake H, Jayasena CS, et al. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surgery. 2021;21:376. PMID: 33588807. https://pubmed.ncbi.nlm.nih.gov/33588807/
Chaudhry HM, Friedman DL, Pidala J, et al. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of Blood and Marrow Transplantation. 2016;22(10):1864–1870. PMID: 26409924. https://pubmed.ncbi.nlm.nih.gov/26409924/
Toman J, Nizam A, Rehman S, et al. Placental Allograft Reconstruction of Cutaneous Wounds Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis. Journal of Drugs in Dermatology. 2025;24(6):e220–e226. PMID: 40327580. https://pubmed.ncbi.nlm.nih.gov/40327580/
Su YN, Zhao DY, Li YH, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: a systematic review and meta-analysis of randomised controlled trials. International Wound Journal. 2020;17(3):753–764. PMID: 32119765. https://pubmed.ncbi.nlm.nih.gov/32119765/
Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. International Wound Journal. 2013;10(5):502–507. PMID: 23742102. https://pubmed.ncbi.nlm.nih.gov/23742102/
Serena TE, Yaakov R, DiMarco D, et al. Dehydrated human amnion/chorion membrane treatment of venous leg ulcers: correlation between 4-week and 24-week outcomes. Journal of Wound Care. 2015;24(11):530–534. PMID: 26551645. https://pubmed.ncbi.nlm.nih.gov/26551645/
Moore KJ. New year, new codes: highlights from CPT and HCPCS 2001. Family Practice Management. 2001;8(1):25–30. PMID: 11317853. https://pubmed.ncbi.nlm.nih.gov/11317853/
Centers for Medicare & Medicaid Services. Final Local Coverage Determinations (LCDs) for Certain Skin Substitutes Withdrawn. Published December 24, 2025. https://www.cms.gov/newsroom/fact-sheets/updating-final-local-coverage-determinations-lcds-certain-skin-substitutes
Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). Published October 31, 2025. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
Centers for Medicare & Medicaid Services. 2020 HCPCS Application Summary, Biannual 2, Drugs and Biologicals. Final decision establishing Q4250 for AmnioAMP-MP. https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-2-2020-drugs-and-biologicals-updated-07312020.pdf

This article is for educational and coding-awareness purposes only and does not constitute legal, billing, or reimbursement advice. Reimbursement and coverage policies change frequently. Verify all coding and billing information with your local Medicare Administrative Contractor and each payer before submitting claims. Product specifications should be confirmed with each manufacturer's current Instructions for Use.